PL1673472T3 - Zastosowanie polimorfizmów genetycznych do przewidywania hepatotoksyczności indukowanej przez leki - Google Patents
Zastosowanie polimorfizmów genetycznych do przewidywania hepatotoksyczności indukowanej przez lekiInfo
- Publication number
- PL1673472T3 PL1673472T3 PL04765830T PL04765830T PL1673472T3 PL 1673472 T3 PL1673472 T3 PL 1673472T3 PL 04765830 T PL04765830 T PL 04765830T PL 04765830 T PL04765830 T PL 04765830T PL 1673472 T3 PL1673472 T3 PL 1673472T3
- Authority
- PL
- Poland
- Prior art keywords
- genetic polymorphisms
- il1a
- hepatotoxicity
- predict drug
- induced hepatotoxicity
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/142—Toxicological screening, e.g. expression profiles which identify toxicity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pathology (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US50897203P | 2003-10-06 | 2003-10-06 | |
| PCT/EP2004/011123 WO2005040415A1 (en) | 2003-10-06 | 2004-10-05 | Use of genetic polymorphisms to predict drug-induced hepatotoxicity |
| EP04765830A EP1673472B1 (en) | 2003-10-06 | 2004-10-05 | Use of genetic polymorphisms to predict drug-induced hepatotoxicity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL1673472T3 true PL1673472T3 (pl) | 2011-07-29 |
Family
ID=34520003
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL04765830T PL1673472T3 (pl) | 2003-10-06 | 2004-10-05 | Zastosowanie polimorfizmów genetycznych do przewidywania hepatotoksyczności indukowanej przez leki |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20070248955A1 (pl) |
| EP (1) | EP1673472B1 (pl) |
| JP (1) | JP4979382B2 (pl) |
| CN (1) | CN1882705A (pl) |
| AT (1) | ATE498021T1 (pl) |
| AU (1) | AU2004283234B2 (pl) |
| BR (1) | BRPI0415299A (pl) |
| CA (1) | CA2540760C (pl) |
| DE (1) | DE602004031352D1 (pl) |
| ES (1) | ES2361018T3 (pl) |
| MX (1) | MXPA06003827A (pl) |
| PL (1) | PL1673472T3 (pl) |
| PT (1) | PT1673472E (pl) |
| WO (1) | WO2005040415A1 (pl) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10262107B1 (en) * | 2013-03-15 | 2019-04-16 | Bao Tran | Pharmacogenetic drug interaction management system |
| CN108949947B (zh) * | 2017-05-25 | 2022-06-28 | 上海市预防医学研究院 | 与抗结核药物性肝损伤发生相关的细胞色素p450基因多态性位点 |
| CN116239665B (zh) * | 2023-03-10 | 2024-08-23 | 山东大学 | Ncf4在制备调控炎症小体激活的制剂中的应用和作为炎症性疾病的治疗靶点中的应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6251598B1 (en) * | 1998-10-30 | 2001-06-26 | Interleukin Genetics, Inc. | Methods for diagnosing sepsis |
| US6214819B1 (en) * | 1998-11-23 | 2001-04-10 | Novartis Ag | Method for treating ocular neovascular diseases |
| AU2001294228A1 (en) * | 2000-10-12 | 2002-04-22 | Takeda Chemical Industries Ltd. | Benzimidazole compounds, process for producing the same and use thereof |
| GB0212648D0 (en) * | 2002-05-31 | 2002-07-10 | Immunoclin Lab Ltd | Treatment with cytokines |
-
2004
- 2004-10-05 US US10/574,768 patent/US20070248955A1/en not_active Abandoned
- 2004-10-05 WO PCT/EP2004/011123 patent/WO2005040415A1/en active Application Filing
- 2004-10-05 AU AU2004283234A patent/AU2004283234B2/en not_active Ceased
- 2004-10-05 AT AT04765830T patent/ATE498021T1/de active
- 2004-10-05 BR BRPI0415299-9A patent/BRPI0415299A/pt not_active Application Discontinuation
- 2004-10-05 CA CA2540760A patent/CA2540760C/en not_active Expired - Fee Related
- 2004-10-05 DE DE602004031352T patent/DE602004031352D1/de not_active Expired - Lifetime
- 2004-10-05 MX MXPA06003827A patent/MXPA06003827A/es active IP Right Grant
- 2004-10-05 PL PL04765830T patent/PL1673472T3/pl unknown
- 2004-10-05 JP JP2006530097A patent/JP4979382B2/ja not_active Expired - Fee Related
- 2004-10-05 CN CNA2004800344189A patent/CN1882705A/zh active Pending
- 2004-10-05 PT PT04765830T patent/PT1673472E/pt unknown
- 2004-10-05 EP EP04765830A patent/EP1673472B1/en not_active Expired - Lifetime
- 2004-10-05 ES ES04765830T patent/ES2361018T3/es not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| JP4979382B2 (ja) | 2012-07-18 |
| ATE498021T1 (de) | 2011-02-15 |
| CA2540760C (en) | 2013-01-08 |
| WO2005040415A1 (en) | 2005-05-06 |
| AU2004283234B2 (en) | 2007-08-30 |
| CA2540760A1 (en) | 2005-05-06 |
| US20070248955A1 (en) | 2007-10-25 |
| BRPI0415299A (pt) | 2006-12-26 |
| EP1673472B1 (en) | 2011-02-09 |
| DE602004031352D1 (de) | 2011-03-24 |
| ES2361018T3 (es) | 2011-06-13 |
| PT1673472E (pt) | 2011-05-12 |
| CN1882705A (zh) | 2006-12-20 |
| EP1673472A1 (en) | 2006-06-28 |
| MXPA06003827A (es) | 2006-06-14 |
| AU2004283234A1 (en) | 2005-05-06 |
| JP2007512231A (ja) | 2007-05-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2007007568A (es) | Variantes geneticas de vkorci que predicen la sensibilidad a la warfarina. | |
| EA200801046A1 (ru) | Неинвазивный способ выявления переходно-клеточной карциномы мочевого пузыря in vitro | |
| EP2311984A8 (en) | Methods and nucleic acids for the analysis of gene expression associated with the prognosis of prostate cell proliferative disorders | |
| ATE527385T1 (de) | Mit tumoren assoziierte genetische variationen | |
| AU2003285866A1 (en) | Methods for assessing efficacy of chemotherapeutic agents | |
| EP3831954A3 (en) | Methods and compositions of molecular profiling for disease diagnostics | |
| WO2006138275A3 (en) | Compositions and methods for treating and diagnosing cancer | |
| EP1492440A4 (en) | NEW PROCEDURE FOR THE DIAGNOSIS AND FORECAST OF MALIGNES DISEASES | |
| MX2007008136A (es) | Metodo para invertir la resistencia multiple en celulas animales. | |
| EP1725967A4 (en) | METHOD FOR GENETIC ANALYSIS | |
| IL182519A0 (en) | Methods and compositions for predicting drug responses | |
| UA90706C2 (ru) | Антагонисты рецептора pgd2 для лечения воспалительных заболеваний | |
| EP2101772A4 (en) | NEUROMUSCULAR BLOCKAGE AGENTS WITH INTERMEDIATE DURATION AND THEIR ANTAGONISTS | |
| IL200120A0 (en) | Compositions, reagents and kits for and methods of diagnosing, monitoring and treating obesity and/or diabetes | |
| DE602004021965D1 (de) | Vertikale arbeitslinie für plattenmaterial | |
| ATE446385T1 (de) | Polymorphismen im nod2/card15 gen | |
| EP1565608A4 (en) | WASHING MACHINE, CONDUCTIVITY SENSOR PROVIDED IN THE WASHING MACHINE AND METHOD OF CONTROLLING THE SAME | |
| EP1905850A4 (en) | METHOD FOR MANUFACTURING STEEL PLATE WITH HIGH COLD-LAMINATED CARBON CONTENT | |
| MX2009004382A (es) | Variaciones geneticas asociadas con tumores. | |
| WO2005034737A3 (en) | Methods for diagnosing and treating endoplasmic reticulum (er) stress diseases | |
| PT1529116E (pt) | Métodos para o tratamento da demência com base no genótipo da apo e | |
| DK1498129T3 (da) | Anvendelse af adenovirusser, muteret i VA generne, til cancerbehandling | |
| MXPA05008793A (es) | Metodos para la prediccion de posibilidad de suicidio durante el tratamiento. | |
| PL1673472T3 (pl) | Zastosowanie polimorfizmów genetycznych do przewidywania hepatotoksyczności indukowanej przez leki | |
| TW200634154A (en) | Apoptosis-specific EIF-5A and polynucleotides encoding same |